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The epidermal growth factor receptor (EGFR/ErbB) pathway plays pivotal roles in cell-cell communication in both vertebrate and invertebrates. In Drosophila and C. 
elegans the EGFR pathway participates in the determination of numerous cell fates, including the development of the compound eye and the vulva. The four EGFR 
orthologs in vertebrates form a layered signaling network that participates in specification of cell fate and coordinates cell proliferation. Mutations in components of the 
pathway are commonly involved in human cancer.
(1) Ligand processing: Different mechanisms are employed in vertebrates and invertebrates for processing the ligand in the signal-producing cell to generate the secret-
ed, active form. In Drosophila, the ligand precursor for Spi, Grk, or Krn is retained in the ER. It associates with the chaperone Star and is trafficked to a late compartment 
where the intramembrane protease Rhomboid resides, cleaving the ligand to generate the secreted form. Rhomboid also cleaves the chaperone Star, thus attenuating 
the level of ligand that is trafficked. In vertebrates, the ligand precursors are trafficked to the plasma membrane, where they are cleaved by ADAM metalloproteases.
(2) Receptor maturation: The nascent forms of EGFR and its sibling, HER2, associate in the ER with a complex comprising the HSP90 chaperone and the kinase-ded-
icated adaptor, CDC37. Upon glycosylation and delivery to the plasma membrane, only the mature form of HER2, as well as some naturally occurring EGFR mutants, 
remain associated with the chaperone. In polarized tissues the PDZ domain proteins LIN-2, -7, and -10 associate with and stabilize the receptor in the basolateral 
surface.
(3) Receptor dimerization: In the absence of a ligand, EGFR exists in a conformation that suppresses kinase activity and restrains formation of receptor dimers. Ligand 
binding initiates a conformational alteration that unmasks a “dimerization loop,” triggering receptor dimerization. These transitions are relayed across the plasma mem-
brane to activate the bilobular kinase domain: the mostly beta-strand N-terminal lobe of one receptor is juxtaposed next to the C-lobe of the dimer partner, thereby 
forming a catalytically active asymmetric dimer. Variations on this activation scheme are found in the ErbB family. ErbB-3 is kinase dead but is able to transactivate 
dimer partners, whereas HER2/ErbB-2 is a ligand-less oncogenic receptor “locked” in the active conformation. Drugs in current clinical use include two EGFR tyrosine 
kinase inhibitors, as well as a dual EGFR and HER2 inhibitor. Also approved for clinical applications are a humanized monoclonal anti-HER2 antibody and two anti-
EGFR antibodies.
(4) Downstream signaling: Receptor homo- or heterodimers undergo transphosphorylation on multiple tyrosine residues. This leads to the recruitment of a plethora of 
enzymes and adaptor proteins. For example, the SHC and GRB2 phosphotyrosine-binding adaptors link phosphorylated receptors, through a guanine nucleotide ex-
change protein (SOS) and a small GTP-binding protein (RAS), to a linear cascade culminating in ERK1 and ERK2, which translocate to the nucleus to stimulate various 
transcription factors. Nuclear translocation of active receptors, such as HER2 and ErbB-4, has also been described.
(5) Switch off: Delayed activation of a variety of suppressive mechanisms attenuates ligand-stimulated signaling or switches cells back to the resting state. These pro-
cesses include receptor ubiquitinylation and dephosphorylation, kinase inactivation, ligand depletion, removal of active receptors from the cell surface, or proteasomal 
degradation. In addition, an inducible set of transcriptional repressors and RNA-binding proteins ensure signal desensitization.
(6) Endosomal sorting: Rapid clearance of active receptors and sorting for degradation in lysosomes involves receptor clustering over clathrin- or caveolin-coated 
regions and CBL-mediated conjugation of ubiquitin or NEDD8. Large ESCRT protein complexes sort ubiquitinylated receptors at the MVB. Independently, inflammatory 
cytokines and oxidative stress transregulate EGFR by phosphorylating and arresting the receptor in perinuclear vesicles.
(7) Adhesion signaling: In some cell types, cell migration is regulated by EGF-induced activation of NCK and PLC-gamma and subsequent activation of RHO family 
GTPases necessary for formation of filopodia and lamellipodia.
Abbreviations
ADAM, a disintegrin and a metalloproteinase; CAMK, calmodulin-dependent protein kinase; DAG, diacylglycerol; DUB, deubiquitinating enzyme; EGFR, epidermal 
growth factor receptor; ER, endoplasmic reticulum; ESCRT, endosomal sorting complex required for transport; GPCR, G protein-coupled receptor; HER2, human 
EGF receptor 2; IP3, inositol (1,4,5)-triphosphate; MAPK, mitogen-activated protein kinase; MKP, MAPK phosphatase; MVB, multivesicular body; NRDP1, neuregulin 
receptor degrading protein 1; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; PLC, 
phospholipace C; PP5, phosphoprotein 5; PS-1, presenilin-1; TACE, tumor necrosis factor alpha converting enzyme; UBD, ubiquitin-binding domain
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